BD继续，罗氏10.7亿美元“赌”临床前双抗，这次荃信生物赚大了？
"罗氏" 相关文章
又有BD大单，罗氏超15亿美元押注翰森制药，MNC的一场“焦虑型投资”？
又有BD大单，罗氏超15亿美元押注翰森制药，MNC的一场“焦虑型投资”？
五家企业相继宣布达成BD授权交易 中国创新药出海热再升温
五家企业相继宣布达成BD授权交易 中国创新药出海热再升温
翰森、普瑞金、维立志博、奥赛康、海和……近日达成五笔BD交易 中国创新药出海热再升温！
创新药出海再下一城！翰森制药与罗氏签订结直肠癌药物授权协议，价值最高14.5亿美元
罗氏/礼来阿尔茨海默病血检产品获批 治疗药物厂商翘首以待
罗氏/礼来阿尔茨海默病血检产品获批 治疗药物厂商翘首以待
2025年，创新药最热门并购赛道浮现
2025年，创新药最热门并购赛道浮现
雷海潮会见美国雅培公司全球董事长兼首席执行官、瑞士罗氏集团董事会主席
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
